Iovance Biotherapeutics (IOVA) Share-based Compensation (2011 - 2026)

Iovance Biotherapeutics (IOVA) has reported Share-based Compensation for 15 consecutive years, with $8.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Share-based Compensation fell 62.03% year-over-year to $8.7 million; the TTM figure through Mar 2026 stood at $8.7 million (down 94.27% YoY), while the FY2025 annual figure was $43.8 million, down 60.05% from the prior year.
• Share-based Compensation climbed to $8.7 million in Q1 2026 per IOVA's latest filing, from -$49.2 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $97.6 million in Q4 2024 and bottomed at -$61.9 million in Q4 2022.
• Historically, Share-based Compensation has averaged $7.9 million across 5 years, with a median of $4.7 million in 2024.
• Annual changes were most pronounced in 2022 — Share-based Compensation sank 218.63% — and 2024, when it surged 10235.33%.
• Iovance Biotherapeutics' Share-based Compensation stood at -$61.9 million in 2022, then surged by 123.28% to $14.4 million in 2023, then surged by 578.17% to $97.6 million in 2024, then slumped by 150.34% to -$49.2 million in 2025, then jumped by 117.7% to $8.7 million in 2026.
• Business Quant data shows IOVA's Share-based Compensation at $8.7 million in Q1 2026, -$49.2 million in Q4 2025, and $11.9 million in Q3 2025.